New drug combo aims to tame tough lung cancer
NCT ID NCT07465757
First seen Mar 23, 2026 · Last updated Jun 12, 2026 · Updated 14 times
Summary
This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel infusions in 21-day cycles, with doses increasing in later groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.